11. Results of the network meta‐analysis per combined oral contraceptive pill.

	Non‐use
	(reference	20 LNG	30 LNG	50 LNG	20 GSD	30 GSD	20 DSG	30 DSG	35 NRG	35 CPA	30 DRSP
	group)
Non‐use	1
20 LNG	2.2 (1.3‐3.6)	1	0.9 (0.6‐1.4)	0.4 (0.2‐0.8)	1.0 (0.6 (1.8)	0.6 (0.4‐1.0)	0.7 (0.4‐1.1)	0.5 (0.3‐0.8)	0.9 (0.5‐1.5)	0.6 (0.3‐1.0)	0.6 (0.4‐0.9)
30 LNG	2.4 (1.8‐3.2)	1.1 (0.7‐1.7)	1	0.5 (0.3‐0.7)	1.1 (0.8‐1.7)	0.7 (0.5‐0.9)	0.7 (0.5‐1.0)	0.6 (0.4‐0.7)	1.0 (0.7‐1.4)	0.6 (0.4‐0.9)	0.6 (0.5‐0.8)
50 LNG	5.2 (3.4‐7.9)	2.3 (1.3‐4.2)	2.1 (1.4‐3.2)	1	2.4 (1.5‐4.0)	1.4 (0.9‐2.1)	1.5 (1.0‐2.4)	1.2 (0.8‐1.8)	2.2 (1.4‐3.3)	1.3 (0.8‐2.1)	1.3 (0.8‐2.1)
20 GSD	2.2 (1.4‐3.2)	1.0 (0.5‐1.7)	0.9 (0.6‐1.3)	0.4 (0.3‐0.7)	1	0.6 (0.4‐0.9)	0.6 (0.4‐1.0)	0.5 (0.3‐0.7)	0.9 (0.6‐1.4)	0.6 (0.4‐0.8)	0.6 (0.4‐0.9)
30 GSD	3.7 (2.8‐4.9)	1.7 (1.0‐2.7)	1.5 (1.2‐2.0)	0.7 (0.5‐1.1)	1.7 (1.1‐2.6)	1	1.1 (0.8‐1.5)	0.9 (0.7‐1.1)	1.5 (1.1‐2.1)	1.0 (0.7‐1.4)	1.0 (0.7‐1.3)
20 DSG	3.4 (2.5‐4.6)	1.5 (0.9‐2.6)	1.4 (1.0‐1.9)	0.7 (0.4‐1.0)	1.6 (1.0‐2.4)	0.9 (0.7‐1.2)	1	0.8 (0.6‐1.1)	1.4 (1.0‐2.0)	0.9 (0.6‐1.3)	0.9 (0.6‐1.3)
30 DSG	4.3 (3.3‐5.6)	1.9 (1.2‐3.1)	1.8 (1.4‐2.2)	0.8 (0.5‐1.2)	2.0 (1.3‐2.9)	1.2 (0.9‐1.5)	1.3 (0.9‐1.7)	1	1.8 (1.3‐2.4)	1.1 (0.8‐1.6)	1.1 (0.8‐1.5)
35 NRG	2.4 (1.7‐3.3)	1.1 (0.7‐1.8)	1.0 (0.7‐1.3)	0.5 (0.3‐0.7)	1.1 (0.7‐1.7)	0.7 (0.5‐0.9)	0.7 (0.5‐1.0)	0.6 (0.4‐0.8)	1	0.6 (0.4‐0.9)	0.6 (0.4‐0.9)
35 CPA	3.9 (2.7‐5.5)	1.7 (1.0‐3.0)	1.6 (1.1‐2.2)	0.7 (0.5‐1.2)	1.8 (1.1‐2.8)	1.0 (0.7‐1.5)	1.1 (0.8‐1.6)	0.9 (0.6‐1.3)	1.6 (1.1‐2.3)	1	1.0 (0.7‐1.5)
30 DRSP	3.9 (2.7‐5.5)	1.7 (1.1‐2.7)	1.6 (1.2‐2.1)	0.7 (0.5‐1.2)	1.8 (1.2‐2.8)	1.1 (0.7‐1.5)	1.1 (0.8‐1.6)	0.9 (0.7‐1.3)	1.6 (1.1‐2.3)	1.0 (0.7‐1.5)	1